# Convatec appoints Jens Viebke as Non-Executive Director

- Link: https://www.directorstalkinterviews.com/convatec-appoints-jens-viebke-as-non-executive-director/4121261233
- Published: 2026-08-27T07:10:00+01:00
- Author: Amilia Stone

**Convatec Group Plc** (LON:CTEC) has announced the appointment of Dr Jens Viebke
as a Non-Executive Director, effective immediately. He also joins the Remuneration
Committee.

Jens brings more than three decades of experience developing and commercialising
healthcare technologies across the life sciences and medical technology sectors,
including leadership roles at Getinge, GE Healthcare Life Sciences and Amersham 
Biosciences. His experience spans R&D, strategy, product development, commercial
operations and general management, and will complement the Board’s expertise in 
innovation, product development and global medtech markets, supporting Convatec’s
continued focus on innovation-driven growth as it executes its Accelerate strategy.

Jens is currently a Non-Executive Director of Bone Support AB, Sedana Medical AB
and Stille AB. He is also Chairman of Epista Life Science.

> **Dr John McAdam CBE, Chair, Convatec, says:** “We are delighted to welcome Jens
> to the Board. He brings extensive international MedTech experience, having held
> leadership roles across research and development, product innovation, strategy
> and business management. His deep understanding of the innovation lifecycle, from
> research through to commercialisation, together with his experience of operating
> in highly regulated healthcare markets, will be a valuable addition to the Board
> as we continue to execute our Accelerate strategy and deliver sustainable growth.”

> **Dr Jens Viebke, Non-Executive Director, Convatec, says:** “I am very pleased
> to be joining John, Jonny and the Convatec team. The company has a strong heritage
> of innovation, particularly clear from its success over the past six years, a 
> clear purpose and leading positions in attractive markets. I look forward to playing
> my part in supporting Convatec to advance its science and innovation agenda, as
> the company delivers its Accelerate strategy and creates long-term value for patients,
> customers, colleagues and shareholders.”

Share on:
